Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Shanghai Bio-Heart Biological Technology Co., Ltd. Class H ( (HK:2185) ).
Shanghai Bio-Heart Biological Technology Co., Ltd. reported a significant reduction in net loss for the year ended December 31, 2024, with a 50.6% decrease from the previous year. The company’s research and development expenses also saw a substantial decline of 63%, reflecting a strategic shift or efficiency improvements. Notably, the Iberis® RDN system received approval from the NMPA for treating resistant hypertension and completed its first commercial procedure in Europe, marking a significant milestone in its market expansion efforts.
More about Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
Shanghai Bio-Heart Biological Technology Co., Ltd. operates in the biotechnology sector, focusing on the development of innovative medical technologies. The company is primarily involved in creating solutions for cardiovascular diseases, with a market focus on treatments for hypertension.
YTD Price Performance: 82.32%
Average Trading Volume: 324,494
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.25B
Find detailed analytics on 2185 stock on TipRanks’ Stock Analysis page.